Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & Administrative
Others
Ratios

Lixte Biotechnology Holdings (LIXT) Research & Development (2016)

Lixte Biotechnology Holdings' Research & Development history spans 7 years, with the latest figure at $150695.0 for Q4 2016.

  • For Q4 2016, Research & Development changed N/A year-over-year to $150695.0; the TTM value through Dec 2016 reached $1.1 million, changed N/A, while the annual FY2025 figure was $254919.0, 64.9% down from the prior year.
  • Research & Development reached $150695.0 in Q4 2016 per LIXT's latest filing, down from $335950.0 in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $5.4 million in Q4 2013 to a low of $150695.0 in Q4 2016.
  • Average Research & Development over 5 years is $823976.6, with a median of $298062.0 recorded in 2014.
  • Peak YoY movement for Research & Development: soared 210.57% in 2015, then crashed 47.68% in 2016.
  • A 5-year view of Research & Development shows it stood at $4.6 million in 2012, then rose by 19.25% to $5.4 million in 2013, then crashed by 94.33% to $309103.0 in 2014, then skyrocketed by 102.01% to $624405.0 in 2015, then tumbled by 75.87% to $150695.0 in 2016.
  • Per Business Quant, the three most recent readings for LIXT's Research & Development are $150695.0 (Q4 2016), $335950.0 (Q3 2016), and $316947.0 (Q2 2016).